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AbsTrACT
Objective Pancreatic ductal adenocarcinoma (PDac) 
still carries a dismal prognosis with an overall 5- 
year survival rate of 9%. conventional combination 
chemotherapies are a clear advance in the treatment 
of PDac; however, subtypes of the disease exist, which 
exhibit extensive resistance to such therapies. genomic 
MYc amplifications represent a distinct subset of PDac 
with an aggressive tumour biology. it is clear that 
hyperactivation of MYc generates dependencies that can 
be exploited therapeutically. The aim of the study was to 
find and to target MYc- associated dependencies.
Design We analysed human PDac gene expression 
datasets. results were corroborated by the analysis of 
the small ubiquitin- like modifier (sUMO) pathway in a 
large PDac cohort using immunohistochemistry. a sUMO 
inhibitor was used and characterised using human and 
murine two- dimensional, organoid and in vivo models of 
PDac.
results We observed that MYc is connected to the 
sUMOylation machinery in PDac. components of the 
sUMO pathway characterise a PDac subtype with 
a dismal prognosis and we provide evidence that 
hyperactivation of MYc is connected to an increased 
sensitivity to pharmacological sUMO inhibition.
Conclusion sUMO inhibitor- based therapies should be 
further developed for an aggressive PDac subtype.
InTrODuCTIOn
Pancreatic ductal adenocarcinoma (PDAC) remains 
a cancer with dismal prognosis reflected by a 5- year 
survival rate of only 9%.1 In contrast to the contin-
uously increasing understanding of molecular and 
genetic alterations of the disease,2 3 therapies are 
not satisfying. Stratified molecular mechanism- 
based therapies are currently emerging4 but are not 
standard of care for the majority of patients.
Disease stratification efforts of PDAC demon-
strate the existence of several subtypes with unique 
biology, phenotypes and therapeutic vulnerabili-
ties.5–14 Such insights indicate that defining subtype- 
specific dependencies will allow for stratification 
and precise molecularly informed therapeutic inter-
vention. These considerations are furthermore 
supported by retrospective investigations15 or the 
COMPASS (NCT02750657) trial,16 which demon-
strate that response to conventional chemothera-
pies differs among subtypes of PDAC.
By controlling genes involved in ribosome 
biogenesis, metabolism, cell cycle and growth, the 
MYC oncogene is a driver in a subset of PDACs.17–19 
Supported by unbiased synthetic lethality screens,20 
it is clear that cancers with a hyperactive MYC 
network are characterised by dependencies, 
which offer the unique possibility for therapeutic 
intervention.17 18 In line with this idea, MYC was 
recently demonstrated to predict responsiveness 
significance of this study
What is already known on this subject?
 ► Current data demonstrate that certain subtypes 
of pancreatic ductal adenocarcinoma (PDAC) 
are completely resistant to clinically used 
chemotherapies.
What are the new findings?
 ► We describe for the first time the relevance of 
the SUMOylation pathway, linked to a poorly 
differentiated phenotype with a poor prognosis. 
PDACs with activation of the small ubiquitin- 
like modifier (SUMO) pathway overlap the 
basal- like subtype.
 ► We detected a cosegregation of the SUMO 
pathway with MYC and observed a functional 
relationship between both pathways.
 ► We demonstrate the relevance of the SUMO 
pathway as a therapeutic target by the use 
of novel SUMO- activating enzyme subunit 
pathway inhibitors and show that MYC 
hyperactivation sensitises PDAC cells towards 
such therapies.
How might it impact on clinical practice in the 
foreseeable future?
 ► SUMO pathway inhibitor- based therapies might 
be a potential approach to target a PDAC 
subtype.
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of PDAC patient- derived xenotransplants or organoids to BET 
inhibitors.21 22
Considering the high potential of MYC to act as a marker for 
patient and therapy selection,18 we set up experiments to deci-
pher dependencies in the subgroup of PDAC with high MYC 
activity. We observed cosegregation of MYC with the SUMOyla-
tion machinery that is connected to sensitivity towards a specific 
small ubiquitin- like modifier (SUMO) inhibitor.
MeTHODs
Compounds, characterisation of suMO inhibitors, and 
chemicals
ML-792 and ML-93 were synthesised by Millennium Pharma-
ceuticals/Takeda (Cambridge, Massachusetts, USA). Biochem-
ical and cellular characterisation of ML-93 activity is described 
in online supplementary materials and methods (SM&M). 
4- hydroxytamoxifen (4- OHT) was purchased from Sigma 
(Sigma, Munich, Germany).
Cell culture and cell line engineering
Description is included in SM&M.
Generation of patient-derived PDAC organoids and primary-
dispersed cell lines
Primary patient- derived PDAC three- dimensional (3D) organ-
oids were generated from primary resected human PDAC 
surgical specimen according to the Tuveson protocol described 
in23 and in the SM&M.24 Generation and culturing of primary- 
dispersed human PDAC cells is described in25 and SM&M. 
Written informed consent from the patients for research use was 
obtained prior to the investigation.
Viability assays, suMO inhibitor (suMOi) treatment, 
clonogenic assay, annexin V, cell cycle-FACs, viability analysis 
by FACs, competitive repopulation assay, Western blotting 
and rnA isolation and expression analysis.
Description is included in SM&M.
Generation of in vivo xenografts and suMOi toxicity
All animal experiments were performed in accordance with 
regional Gothenburg University animal ethics committee 
approval 100/16 and 5.8.18-01949/2018 and approval of 
Regierung von Oberbayern ROB-55.2–2532.Vet_02-17-230. A 
detailed description can be found in the SM&M section.
rnA-seq analysis, gene expression profiling, gene set 
enrichment analysis (GseA), transcriptomics and genomics 
data analysis
Description is included in SM&M.
Clinical PDAC patient cohort, histological analysis and 
immunohistochemistry
Tissue microarrays and analysis of human PDAC cohort (n=262) 
are described in SM&M. The use of this tumour cohort for 
biomarker analysis has been approved by the Charité University 
ethics committee (EA1/06/2004).
Proteome analysis by mass spectrometry
Proteome analysis is described in detail in SM&M.
statistical methods
Analysis of variance or two- sided t- test was used. P values were 
corrected according to Bonferroni for multiple testing. Values 
were calculated with GraphPad Prism6/8. P values are indi-
cated or represented with: *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. Data are presented as mean and SD.
resulTs
MYC is connected to the sumoylation pathway in PDAC
A recent study demonstrated that amplification of MYC is the sole 
copy number variation (CNV) associated with poor prognosis 
in PDAC.26 To further substantiate these findings, we assessed 
TCGA- PAAD data. Twelve per cent of PDACs in this dataset 
harbour MYC amplifications connected to reduced overall 
survival and disease- free survival (figure 1A). Using GSEA via 
the GeneTrail2 1.6 web service, which uses an unweighted GSEA 
methodology,27 we detected activation of the MYC network in 
MYC- amplified cancers (figure 1B). Following the concept that 
hyperactivity of the MYC network is connected to specific 
dependencies in PDAC,17 18 we analysed further pathways active 
in MYC- amplified cancers (online supplementary table S1). We 
detected significant enrichment of Reactome signatures linked to 
protein SUMOylation as well as curated core SUMO pathways in 
MYC- amplified PDACs (figure 1C,D). Since the SUMO pathway 
was found to be an MYC- associated dependency in an unbiased 
genome- wide genetic screen in human mammary epithelial cells 
(HMECs),28 an observation which could also be made in other 
neoplasms such as B- cell lymphomas,29 we explored the possi-
bility that the SUMO pathway confers a vulnerability in PDAC 
with hyperactivity of MYC. SUMO modification of cellular 
proteins is an important post- translational modification (PTM) 
that regulates function, localisation, interaction and expression 
of proteins. PTM by SUMOs has been reported to play various 
important roles in tumourigenesis.30 Analogous to ubiquitina-
tion, SUMO1, SUMO2 or SUMO3 are transferred to lysine resi-
dues of proteins in a multistep catalytic process involving the E1 
activating enzymes SUMO- activating enzyme subunit 1 (SAE1) 
and 2 (UBA2/SAE2), the E2 conjugating enzyme UBE2I (UBC9) 
and SUMO E3 ligases.30 31 Next- generation sequencing data26 
demonstrated MYC amplifications as well as CNVs of the SUMO 
pathway genes SAE1 and UBE2I (figure 1E), furthermore under-
scoring the importance of both pathways in PDAC.
relevance of the sumoylation pathway in PDAC
To further investigate the relevance of the SUMOylation pathway, 
we compared the expression profiles of 69 PDACs to 61 adjacent 
non- tumour tissue samples32 and observed an increased expres-
sion of the SUMO pathway components SAE1, UBE2I, SUMO1, 
SUMO2 and SUMO3 in PDAC (online supplementary figure 
S1A), underlined by a corresponding enrichment of SUMO- 
related gene sets in PDAC (online supplementary figure S1B). 
Analysing the TCGA clinical data set demonstrated that high 
expression of UBE2I is linked to a worse prognosis (figure 2A), an 
observation valid also for SUMO1 (figure 2B). The Kaplan- Meier 
curves for PDAC with high and low SUMO2 and SUMO3 mRNA 
levels are depicted in figure 2C,D. Comparing the UBE2I high 
and low groups by GSEA demonstrated the enrichment of MYC 
signatures in UBE2I high PDACs (figure 2E). MYC signatures 
were also detected in PDACs with high expression of SUMO1, 
SUMO2 and SUMO3 mRNA (online supplementary figure 
S1C), again corroborating the connection of both pathways. To 
further stress the significance of the core SUMOylation pathway 
for PDAC, we analysed an additional PDAC mRNA expression 
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Figure 1 MYC is connected to the SUMOylation pathway in PDAC. (A) genomic MYC amplification (23/183 cases, 12%) is correlated with inferior 
overall survival (OS) (median OS 15.11 vs 20.83 months; n=183; p=0.033) and disease- free survival in PDAC (median DFS 7 vs 17.28 months; 
n=141; p=0.003) (data are based on the TCGA- PAAD dataset). (B) Unweighted GSEA using gene Trail2 1.6 comparing MYC amplified and non- 
amplified PDACs. q values are depicted. (C, D) Unweighted GSEA using gene Trail2 1.6 reveals significant enrichment of gene sets involved in 
protein sumoylation within the MYC amplified PDAC subgroup. Enrichment analysis was performed for published Reactome pathways (C), SUMO 
is transferred from E1 to E2 (UBE2I, Ubc9); sumoylation of DNA replication proteins and manually curated core SUMO pathway gene sets (D), 
core SUMO pathway SAE1, UBA2, UBE2I; SUMO pathway and paralogs SAE1, UBA2, UBE2I, SUMO1, SUMO2, SUMO3. q values are depicted. (E) 
Published genomics data from whole exome sequencing of 109 microdissected pancreatic cancer cases26 demonstrates a tendency towards mutual 
exclusivity in genomic MYC and SUMO pathway components (SAE1, UBE2I) aberrations. GSEA, gene set enrichment analysis; PDAC, pancreatic ductal 
adenocarcinoma; SAE1, SUMO- activating enzyme subunit 1; SUMO, small ubiquitin- like modifier.
dataset from 96 patients,7 where we detected a human PDAC 
subtype with increased expression of core SUMO pathway genes 
(SUMOhigh) (figure 2F). Comparing the SUMOhigh subtype with 
the SUMOlow subtype by the GeneTrail2 demonstrated enrich-
ment of MYC signatures (online supplementary figure S1D). A 
complete list of pathways active in the SUMOhigh subtype is listed 
in online supplementary table S2. Also in this human PDAC 
dataset, the SUMOhigh PDACs were characterised by decreased 
progression- free as well as overall survival (online supplementary 
figure S1E). PDAC subtyping efforts have shown the existence 
of several subtypes and squamous/basal- like/quasi- mesenchymal, 
classic/progenitor, immunogenic and aberrantly differentiated 
endocrine exocrine- subtypes were described, although not all 
of these subtypes were found to be stable/reproducible.33 The 
recurrently identified and therefore currently generally accepted 
squamous/basal- like/quasi- mesenchymal subtype carries the 
worst prognosis.5–8 10 12 SUMOhigh PDACs are characterised by 
an enrichment of squamous subtypes (figure 2F,G) and poorly or 
undifferentiated tumours (figure 2F, H).
To further substantiate the relevance of the SUMOyla-
tion pathway in PDAC, we analysed SUMO1, and SUMO2/3 
expression in an additional human PDAC cohort (n=262) at 
the protein level using immunohistochemistry (IHC). Here, we 
observed PDACs with low, intermediate or high SUMO1 and 
SUMO2/3 expression (figure 2I). Consistent with the RNA 
expression- based analysis, the SUMO1- high phenotype was 
associated with less differentiated tumours (figure 2J). In addi-
tion, we detected a connection of high SUMO1 expression to 
younger patients (figure 2K) and female gender (figure 2L). 
Multivariate survival analysis demonstrated a connection of 
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Figure 2 SUMOylation components are induced in PDAC and associated with adverse prognosis. (A–D) Transcriptomics data (TCGA- PAAD) was 
analysed for correlation of SUMO pathway component transcript levels and survival rates. Overall survival of patients with high expression of UBE2I, 
SUMO1, SUMO2 or SUMO3 mRNA (>75th percentile) was compared with overall survival of patients with low mRNA expression of these genes 
(<25th percentile). High expression of UBE2I and SUMO1 mRNA is significantly associated with decreased overall survival. P value of a logrank 
test is depicted. All survival curves were directly retrieved via the OncoLnc platform (http://www.oncolnc.org/) using the above defined thresholds. 
(E) Unweighted GSEA of UBE2I- high and low groups using gene Trail2 1.6 reveals significant enrichment of MYC hallmark target genes within 
UBE2I- high subgroup (thresholds defined in A–D). Q value is depicted. (F) Manual curation of a publicly available gene expression dataset of PDAC 
patients (n=96)7 was used to define a SUMO- high population, characterised by positive z- scores for SAE1, UBA2 and UBE2I (n=14). (G, H) SUMO 
high PDACs corresponding to 2F were analysed for association with tumour differentiation or subtype. (G) Enrichment of the squamous subtype 
and (H) enrichment of undifferentiated and poorly differentiated tumours in the SUMO high subtype. P values of a Fisher’s exact test are indicated. 
(I) Representative IHC staining of surgical PDAC specimen (n=262) with low, intermediate and high SUMO1 or SUMO2/3 expression. (J–L) Nuclear 
SUMO1 expression is significantly enriched in biologically aggressive G3 tumours as well as in younger patients, that is, <65 years of age and female 
patients. The P values of a Pearson's X2 test are depicted. G1: well differentiated, G2: moderately differentiated, G3: poorly differentiated PDAC. (M) 
Combined SUMO1 and SUMO2/3 nuclear expression as measured by IHC is correlated with an adverse prognosis in PDAC patients. The p value of a 
logrank test is shown. (N) MYC IHC was conducted in the above- described PDAC cohort. PDACs were grouped in tumours with positive and negative 
MYC staining and connected to the SUMO1 status. The p value of a Pearson's X2 test is depicted. (O) A multivariate analysis reveals a prognostically 
favourable subpopulation of patients with low MYC-/SUMO expression that exhibits the best clinical course (p=0.018, logrank) independent of 
initial Union for International Cancer Control (UICC) stage. GSEA, gene set enrichment analysis; IHC, immunohistochemistry; PDAC, pancreatic ductal 
adenocarcinoma; SEA1, SUMO- activating enzyme subunit 1; SUMO, small ubiquitin- like modifier.
the SUMOylation pathway to reduced survival (figure 2M). To 
further demonstrate the connection of the SUMO pathway to 
MYC, we analysed MYC protein expression using IHC in the 
same cohort. MYC positive tumours were significantly enriched 
in the SUMO1 high phenotype (figure 2N). Furthermore, multi-
variate analysis reveals that survival of patients belonging to the 
MYClow/SUMOlow subtype is significantly better compared with 
all other subgroups (figure 2O). Together, mRNA and protein 
expression data in large human PDAC cohorts demonstrate 
that the SUMOylation pathway characterises a subset of poorly 
differentiated PDACs with a significant enrichment of squamous/
basal- like tumours. Furthermore, a subset of PDAC coactivates 
the SUMO pathway and MYC.
MYC connects to the suMOylation pathway in PDAC cells
To additionally analyse the connection of MYC to the SUMOyla-
tion pathway, we used human PDAC cell lines, where we detected 
a positive correlation of MYC mRNA with the expression of 
SUMO1 (p=0.01) and SUMO2 (p=0.09) mRNA (figure 3A). A 
positive correlation of the MYC mRNA to genes of the SUMO 
pathway was also detected in murine PDAC cell lines (online 
supplementary figure S2A). We quantified MYC protein expres-
sion in ten human PDAC cell lines (figure 3B,C). Higher MYC 
expression was connected to higher levels of total SUMO1 and 
SUMO2/3 conjugated proteins (figure 3D). To demonstrate the 
induction of the SUMO pathway by MYC in human PDAC cell 
lines, we used an MYC oestrogen receptor fusion protein (MYCER) 
in IMIM- PC1 cells (figure 3E), which express low levels of MYC 
(figure 3B,C). Activation of MYC by 4- OHT treatment induced 
the expression of classical MYC target genes including ODC1 and 
CAD (figure 3F). In RNA- seq experiments, we observed MYC 
signatures activated on 4- OHT treatment (figure 3G), demon-
strating the anticipated activation of the MYC network. Signatures 
connected to the SUMO pathway were coactivated on 4- OHT 
treatment (figure 3H and online supplementary table S3). In addi-
tion to these gain- of- function data, we analysed RNA- seq data, in 
which MYC was potently inhibited in murine PDAC cells using a 
dominant- negative form of MYC, called OmoMYC.34 OmoMYC 
coinhibited the MYC network and signatures connected to the 
SUMO pathway (online supplementary figure S2B). In addi-
tion, we transduced murine PDAC cells with vectors driving the 
expression of GFP or MYC together with GFP (figure 3I,J). In 
GSEA of RNA- seq of these cells, we detected the activation of the 
MYC pathway (figure 3K) and signatures connected to SUMOy-
lation (figure 3L). A slight increase in protein SUMOylation was 
observed in SUMO1 and SUMO2/3 western blots in MYC overex-
pressing cells (figure 3M). The GO_PROTEIN_SUMOYLATION 
signature contains the core SUMO pathway genes Sumo1-3, Sae1, 
Sae2/Uba2 and Ube2i, which were upregulated in MYC over-
expressing PPT-53631 cells comparable to MYC target genes 
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Figure 3 MYC activation induces SUMOylation pathway components. (A) SUMO1 and SUMO2 mRNA expression correlate with MYC expression 
across the depicted conventional human PDAC cell lines. Pearson R and p values are indicated. n=2; all biological replicates were performed as 
technical duplicates. (B, C) MYC protein expression quantification by Western blot in human PDAC cell lines. Actin: loading control. (B) Representative 
MYC Western blot; (C) Quantification of the MYC Western blots. Protein expression of MYC in DanG cells was arbitrarily set to 1. Each dot represents 
a biological replicate. HPAF- II cells are not included in the representative Western blot of (B). Shown is the mean±SD. (D) representative Western 
blots of SUMO1 and SUMO2/3 in human PDAC cell lines. Actin: loading control. (E) MYC Western blot of IMIM- PC1MYC- ER and IMIM- PC1 cells. Actin: 
loading control. (F) qPCR of MYC, ODC1 and CAD in IMIM- PC1MYC- ER cells. MYC downstream effectors ODC1 and CAD are induced 24 hours after the 
treatment of IMIM- PC1 with 4- OHT at 500 nM. n=3; all biological replicates were performed as technical duplicates. P value of a paired t- test.(G, H) 
GSEA of RNA- Seq data of IMIM- PC1MYC- ER treated for 24 hours with 4- OHT compared with vehicle controls. (I–M) The murine PDAC cell lines PPT-
53631 and PPT-5671 were transduced with a GFP or an MYC- IRES- GFP vector. (I) MYC and GFP Western blot in parental, GFP- transduced and MYC- 
IRES- GFP- transduced cells. GAPDH: loading control. (J) Quantification of MYC expression corresponding to (I). Each circle represents quantification of 
a biological replicate. (K, L) GSEA of RNA- Seq data of GFP- transduced and MYC- IRES- GFP- transduced PPT-53631 cells. (M) Representative SUMO1 
and SUMO2/3 Western blots of the indicated GFP- transduced and MYC- IRES- GFP- transduced cells; tubulin: loading control. (N) RNA- seq data of 
GFP- transduced and MYC- IRES- GFP- transduced PPT-53631 cells were analysed for the expression of Myc target genes and core SUMO pathway 
genes. Shown is the colour- coded log FC (fold change). mRNAs upregulated with an adjusted p<0.05 are marked by *. *P<0.05, **P<0.01. FDR, 
false discovery rate q value (GSE119423); 4- OHT, 4- hydroxytamoxifen; GSEA, gene set enrichment analysis; NES, Normalised Enrichment Score; PDAC, 
pancreatic ductal adenocarcinoma; SUMO, small ubiquitin- like modifier.
(figure 3N). Whether upregulation by MYC occurs directly or 
indirectly, is unclear and may vary with context. Together, across 
PDAC models and species, a functional connection of MYC to 
the SUMOylation machinery was observed, which supports the 
hypothesis of a specific vulnerability for inhibition of the SUMOy-
lation pathway in MYC hyperactivated PDACs.
suMO pathway inhibition induces G2/M phase arrest and 
apoptosis
To investigate whether the SUMOylation machinery is a relevant 
therapeutic target, we tested the activity of two small- molecule 
inhibitors of SAE. The selective SAE inhibitor ML-792 was 
demonstrated to inhibit SAE and SUMO- pathway activities.35 
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In breast, lung and colon cancer lines, ML-792 acts in an half- 
maximal effective concentration (EC50) range of 60–450 nM to 
inhibit cell viability.35 The dose–response curves measured with 
an MTT- viability assay of ML-792 in six human PDAC cell lines 
are shown in online supplementary figure S3A. The ML-792 half- 
maximal growth inhibitory (GI50) concentrations in the PDAC 
lines are higher than the ones described in breast, lung and colon 
cancer lines35 (online supplementary figure S3A). ML-93 is also 
a potent inhibitor of SAE, as measured in the ATP- inorganic 
pyrophosphate exchange assay, with a half- maximal inhibitory 
concentration of 37 nM when incubated with SUMO2, compa-
rable to that reported for ML-792.35 Assessment of cellular 
activity and selectivity of ML-93, measured by means of thio-
ester assays, demonstrated potent inhibition of SAE with a EC50 
value of 1 nM for inhibition of the UBC9- SUMO thioester, and 
dose- dependent decrease in global SUMOylation (online supple-
mentary figure S3B). In contrast, EC50 values for inhibition of 
UBC12 and UBC10 thioesters by ML-93 were both >5000 nM, 
demonstrating strong selectivity of ML-93 for inhibition of the 
SUMO pathway relative to the NEDD8 and ubiquitin pathways.
ML-93 reduced growth (figure 4A) and clonogenic growth in 
the low nanomolar range (online supplementary figure S4A,B). 
In MiaPaCa2 and PSN1 cells, ML-93 increased the fraction of 
apoptotic cells in a dose- dependent and time- dependent manner 
(figure 4B). The apoptotic fraction is higher in MYC- amplified 
PSN1 cells. In MiaPaCa2 cells, ML-93 significantly reduced the 
fraction of cells in the G1 and S phases of the cell cycle with a 
distinct increase detected in the fraction of cells in the sub- G1 
phase, demonstrating that apoptosis is a major contributor to 
the response (figure 4C). In addition, cells accumulated in the 
G2/M phase and we detected polyploidization on treatment with 
ML-93 (figure 4C). Loss of cells in the G1 phase of the cell cycle, 
polyploidization and induction of a sub- G1 population on treat-
ment with ML-93 were also detected in PSN1 and PaTu- 8988T 
cells (online supplementary figure S4C,D).
Pathways modulated on suMOi and efficacy in MYC 
hyperactivated PDAC
To monitor inhibition of the pathway, we determined SUMOy-
lation of the known SUMO substrate RanGAP1 in PaTu- 8988T 
cells.36 RanGAP1 is completely SUMOylated in PaTu- 8988T 
cells and ML-93 induced the appearance of un- SUMOylated 
RanGAP1, demonstrating on- target activity (online supplemen-
tary figure S5A). RNA- seq of ML-93 treated PaTu- 8988T cells 
showed that SUMOylation signatures were depleted (online 
supplementary figure S5B). To find pathways coinhibited by 
ML-93, we analysed RNA- seq data of three ML-93 treated 
human PDAC cell lines. Transcriptomic changes observed 
on ML-93 treatment were rather small and highly context 
dependent (online supplementary figure S5C). Also, pathways 
connected to ML-93- regulated genes varied with context (online 
supplementary figure S5D). Online supplementary figure S5E 
demonstrates MSigDB- derived hallmark signatures associated 
with ML-93 regulated genes, which were detected in all analysed 
cell lines. In addition to transcriptomics, we analysed ML-93- 
induced changes in protein expression on a global scale. Again, 
changes observed in the proteome analysis were rather moderate 
(online supplementary figure S5F).
To analyse the connection of SUMOi sensitivity to MYC 
activity, we used a large panel of human and murine PDAC cell 
lines. We determined GI50 values in 17 human conventional 
PDAC lines (figure 4D), and observed a distinct heterogeneity 
in the responsivity. Although MYC protein expression in whole 
cell lysates does not necessarily correlate with MYC’s overall 
transcriptional activity, a consideration recently described in 
PDAC models,21 human PDAC lines with higher MYC protein 
expression demonstrated activation of the MYC transcriptional 
network in GSEA (online supplementary figure S6A). These lines 
were characterised by significantly lower GI50 values (figure 4E). 
To validate our findings across different species, we used a 
KrasG12D- and PI3K/p110H1047R- driven murine PDAC cell line 
collection37 38 and determined the GI50 values of ML-93 and 
ML-792 in 48 lines. GI50 values of ML-792 and ML-93 showed 
a significant correlation (figure 4F). We next investigated the 
connection of MYC with the sensitivity towards SUMOi at 
several levels. First, we analysed MYC protein expression in 
the most ML-93 sensitive (marked in blue in figure 4F) to the 
most resistant murine PDAC lines (marked in red in figure 4F). 
Murine ML-93 sensitive lines demonstrate higher MYC protein 
expression (figure 4G, H). In addition, we analysed RNA- seq 
data.38 We defined murine PDAC lines which were sensitive or 
resistant to both SUMOi. Again, we observed an MYC signa-
ture in the sensitive cell lines (figure 4I). Third, we correlated 
the expression values of all transcripts of the murine expression 
dataset with the GI50 values for ML-792 and ML-93, deter-
mined Pearson correlation coefficients, and used these as a rank 
to run a preranked GSEA. Among the HALLMARK signatures 
associated with GI50 negatively correlated genes, both MYC 
HALLMARK signatures were detected (online supplementary 
figure S6B,C). Beyond demonstrating the correlation of MYC 
to SUMOi sensitivity, we used mechanistic data and models to 
functionalise the connection. We used the Project Score data-
base (https:// score. depmap. sanger. ac. uk/), which is based on a 
functional CRISPR/Cas drop- out screen.39 The loss of fitness 
scores for MYC and UBE2I in 23 human PDAC cell lines were 
compared. A significant correlation of both scores was observed 
(figure 4J), supporting the notion, that MYC- addicted lines are 
coaddicted to the SUMO pathway. To further substantiate the 
finding that the SUMO pathway is an MYC- associated depen-
dency, we used isogenic murine PDAC models. Such isogenic 
models are appropriate to find and define genotype- specific 
drug responses.40 First, we used the MYC- IRES- GFP transduced 
cell lines PPT-53631 and PPT-5671 to perform a repopulation 
assay, allowing to monitor ‘MYC- high’ and ‘MYC- low’ popu-
lation dynamics over time. Compared with GFP- transduced 
controls, MYC overexpressing cells showed a significant growth 
disadvantage under ML-93 treatment (figure 4K). Furthermore, 
a higher fraction of apoptotic cells was observed in MYC- 
transduced cells on SUMOi (figure 4L) and ML-93- dependent 
clonogenic growth inhibition was augmented by ectopic MYC 
expression (figure 4M). To further substantiate these findings, 
we used conditional MYC overexpression. First, murine PDAC 
lines were transduced with an MYCER coding vector (online 
supplementary figure S7A,B) and the response to ML-93 was 
measured in the presence (MYC on) or absence (MYC off) of 
4- OHT. In all investigated models, the ML-93 dose response was 
shifted to the left in the presence of 4- OHT (online supplemen-
tary figure S7C), indicating a higher sensitivity. In PPT-53631 
cells, mock transduced with the empty vector, 4- OHT does not 
change the ML-93 dose response, demonstrating a specific MYC 
effect (online supplementary figure S7C, far right panel). Also in 
clonogenic assays, the SUMOi response was augmented by acti-
vation of MYC (online supplementary figure S7D,E). To cross- 
species validate these findings, we used human IMIM- PC1MYCER 
cells. Again, the dose response of both SUMOi was shifted to the 
left (online supplementary figure S7F), demonstrating that MYC 
hyperactivation generates a vulnerability which can be exploited 
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Figure 4 SUMOylation inhibition targets an MYC- associated vulnerability.(A) Growth kinetics reveal dose- dependent and time- dependent 
reduction of cell growth under ML-93 treatment. PSN1 cells were treated with varying concentrations of ML-93 for the indicated time points. 
Viable cells, determined by trypan blue exclusion, were determined at the indicated time points and relative growth is depicted. All replicates (n=3) 
were performed as technical triplicates. (B) ML-93 induces apoptosis as measured by annexin V/PI flow cytometric analysis at low nanomolar 
concentrations after treatment periods of 24 hours, 48 hours and 72 hours. All replicates (n=3) were performed as technical triplicates. ANOVA. 
**p<0.01, ***p<0.001, ****p<0.0001. (C) ML-93 induces G2/M cell cycle arrest as demonstrated by PI cell cycle flow cytometry analyses. 
Shown are the proportions of cells in the sub- G1, G1, S and G2/M phases after ML-93 treatment for 24 hours and 48 hours. All replicates (n=3) 
were performed as technical triplicates. ANOVA: **p<0.01, ***p<0.001, ****p<0.0001. (D) The growth inhibitory concentration 50% (GI50) was 
determined in 17 human PDAC cell lines. ATP (CellTiter- Glo assay) was used as a surrogate to determine the dose response of a 7- point ML-93 dilution 
(0–1000 nM). Cells were treated for 72 hours. The assay was performed with at least three biological replicates conducted as technical triplicates. 
GI50 values >1000 nM were extrapolated from the fitted curve. (E) GI50 values of human PDAC lines with low and high MYC protein expression were 
compared. High expression: MYC protein expression >66th percentile; low expression: MYC protein expression <66th percentile (see figure 3C). 
*P value of an unpaired t- test <0.05. (F) GI50 for ML-93 and ML-792 was determined in 48 murine PDAC cell lines by MTT- assay. Determined was a 
dose response of 7- point dilution (ML-93: 0–1000 nM; ML-792: 0–5000 nM). Cells were treated for 72 hours. The assay was performed with at least 
three biological replicates conducted as technical triplicates. GI50 values >1000 nM for ML-93 and >5000 nM for ML-792 were extrapolated from the 
fitted curve. The Pearson correlation coefficient of ML-93 and ML-792 and the p values are depicted. Blue dots: ML-93 sensitive lines; red dots: ML-93 
resistant lines. (G) MYC Western blot of the ML-93 sensitive and the ML-93 resistant murine PDAC cell lines. Actin: loading control. (H) Quantification 
of MYC expression in ML-93 sensitive and the ML-93- resistant murine PDAC cell lines, corresponding to (G). Mean MYC expression of three different 
lysates for each line, each normalised to actin. *P value of an unpaired t- test <0.05. (I) Unweighted GSEA analysis using the GeneTrail2 platform of 
SUMO inhibitor sensitive and resistant murine PDAC cell lines. Sensitive lines: common lines for which the ML-93 and the ML-792 GI50 values were 
<25th percentile. Resistant lines: common lines for which the ML-93 and the ML-792 GI50 values were >75th percentile. Q- value is depicted. (J) Loss 
of fitness scores were derived from the project score database (https://score.depmap.sanger.ac.uk/). Shown is the correlation of the scores for MYC 
and UBE2I in 23 human PDAC cell lines. The Pearson correlation coefficient and the p value are depicted. (K) Competitive repopulation assay. PPT-
53631 and PPT-5671 cells transduced with a GFP or MYC- IRES- GFP vector were cocultured with corresponding wild type cells in a 20:80 ratio on 
D0. The proportion of GFP positive cells was tracked and reassessed on D5 by flow cytometry. The relative fold change was measured as the relative 
difference in the fraction of GFP positive cells on D5 versus baseline (d0). ML-93 (500 nM) treatment groups were normalised to the corresponding 
dimethylsulfoxide (DMSO)- treated controls and are depicted relative to all measured cells. All biological replicates (PPT-53631: n=3; PPT-5671: n=4) 
were performed as technical duplicates. P value of an unpaired t- test **<0.01, **<0.001. (L) Murine PPT-53631 or PPT-5671 PDAC cells, transduced 
with GFP or MYC- IRES- GFP vectors were treated with 50, and 500 nM ML-93 for 72 hours. The fraction of apoptotic cells was determined by annexin 
V/DAPI flow cytometric analysis. All annexin V positive and DAPI negative cells were rated as apoptotic. Four independent experiments are shown 
and each experiment is depicted as a circle. P value of an unpaired t- test **<0.01; *<0.05. (M) Quantification of clonogenic assays in parental, GFP 
or MYC- IRES- GFP vector transduced murine PPT-53631 and PPT-5671 PDAC cell lines. Cells were treated with the indicated ML-93 doses. Assay was 
performed with at least three biological replicates in technical duplicates. P value of an unpaired t- test: *<0.05, **<0.01, ****<0.0001. ANOVA, 
analysis of variance; GSEA, gene set enrichment analysis; PDAC, pancreatic ductal adenocarcinoma; SUMO, small ubiquitin- like modifier.
through SUMOi. To extend this note to the genetic level, we 
used Ube2i RNA interference in MYC overexpressing models. 
However, due to a distinct counterselection, we were not able 
to achieve a meaningful knock- down. In an assumption that 
SUMOi resistant cells will better tolerate the Ube2i knock- down, 
we transduced such a cell line with an MYCER vector (online 
supplementary figure S7G,A). However, also here, only one 
of the tested shRNAs induced a Ube2i knockdown to approxi-
mately 50% compared with control (online supplementary figure 
S7H). Despite this modest knock- down, activation of MYC by 
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4- OHT is less tolerated in Ube2i- depleted cells, underscoring the 
connection of both pathways (online supplementary figure S7I).
suMOi sensitivity in human PDAC ex vivo and in vivo models
To elucidate first evidence for in vivo activity of ML-93, we used 
xenograft transplantation models. First, we determined in vivo 
toxicity of ML-93 in C57BL/6 mice (online supplementary figure 
S8A). No significant change in body weight (online supplemen-
tary figure S8B), haemoglobin concentration, white blood cells 
or platelets counts were detected (online supplementary figure 
S8C). SUMO2/3 western blots of splenocyte protein lysates 
demonstrated on- target activity (online supplementary figure 
S8D,E). Of note, only in immunodeficient mice, we observed 
ML-93- induced skin irritation and ulceration at the injection site. 
To investigate activity of ML-93 against PDAC in vivo, we trans-
planted PaTu- 8988T cells s.c. into immunocompromised NOG 
mice and treated tumor- bearing mice with ML-93 (figure 5A). 
Growth of PaTu- 8988T xenografts was inhibited by ML-93 
(figure 5B,C). To monitor inhibition of the pathway in vivo, we 
determined again SUMOylation of RanGAP136 (figure 5D) and 
observed reduced SUMOylation of RanGAP1 (figure 5E). In 
addition to PaTu- 8988T, we tested ML-93 in PSN1, HuPDAC7, 
BxPc3 and IMIM- PC1 in vivo models (online supplementary 
figure S8F- J). Although the proliferation index was reduced 
by ML-93 in the PSN1 in vivo model, tumour growth was not 
altered in any of the investigated models in the limited- duration 
treatment schedule used.
To investigate the connection of MYC with the sensitivity 
towards SUMOi in primary human ex vivo models, we used 
patient- derived organoids (PDOs) and primary- dispersed human 
PDAC cell lines. PDOs are 3D models suitable to evaluate clini-
cally relevant therapeutic vulnerabilities.41–43 Consistent with the 
two- dimensional cultures, ML-93 was found to inhibit viability 
in the double- digit nanomolar range in three out of four of the 
investigated PDO models, whereas one PDO completely resisted 
ML-93 treatment (online supplementary figure S9A). Although 
the moderate number of organoids analysed clearly limits the 
informative value, the resistant PDO showed the lowest MYC 
mRNA expression (online supplementary figure S9B). Such 
observations underscore the requirement to stratify patients 
for SUMO pathway targeting drugs. Complementary to PDO 
models, we used primary- dispersed human PDAC cell lines. We 
first analysed the MYC expression and SUMO status in three 
lines and observed a gradual increase in MYC protein expres-
sion from HuPDAC3, to HuPDAC17 and HuPDAC7 (figure 5F 
and online supplementary figure S9C). Gradual increase in MYC 
expression is correlated to an increase in SUMO1 and SUMO2/3 
modified proteins (figure 5G). MYC target genes and SUMO- 
pathway genes showed lower expression at the mRNA level 
in HuPDAC3 cells (figure 5H), demonstrating that the MYC/
SUMO ‘high’ subtype we described in PDAC, was recapitulated 
by the primary- dispersed human PDAC cell lines. Importantly, 
the MYC/SUMO expression status is connected to the sensitivity 
towards SUMOi as demonstrated by different GI50 values and 
inhibition of clonogenic growth (figure 5I–K; online supplemen-
tary figure S9D). Consistently, the fraction of apoptotic cells was 
higher in HuPDAC7 cells on SUMOi compared with the line 
with low MYC expression (figure 5L).
DIsCussIOn
The ability to target molecularly defined tumour subtype- specific 
drivers is a successful strategy and has changed the standard of 
care in solid tumour entities. Although the existence of different 
subtypes in PDAC is undisputed, therapeutically exploitable 
subtype- specific drivers and resulting dependencies were so far 
unknown for the majority of patients. In this study, we provide 
for the first- time evidence for the existence of a PDAC subtype 
characterised by the coactivation of the MYC and SUMO path-
ways and connected to a worse prognosis. We detected an enrich-
ment of tumours coactivating MYC and SUMO in the basal- like/
squamous subtype of the disease, a subtype especially resistant to 
chemotherapies.15 16 We show a mechanistic relationship of the 
MYC oncogene to the SUMOylation machinery in PDAC and 
provide evidence that MYC hyperactivation increases the sensi-
tivity to SUMO pathway inhibition.
One strategy to target MYC is to identify synthetic dosage 
lethal interactions associated with hyperactivity of this tran-
scription factor.17 18 20 The utility of such a concept is under-
scored by the results of a genome- wide shRNA MYC synthetic 
lethality screen in HMECs, where SUMOylation pathway 
members, including SAE2/UBA2, SAE1 or UBE2I, were defined 
as synthetic lethal MYC interactions.28 Additionally, UBE2I was 
detected in an MYC synthetic lethal screen in human foreskin 
fibroblasts,44 demonstrating the robust synthetic lethal rela-
tionship of MYC and the SUMO pathway. Genetic interference 
with the SUMOylation pathway in the MYC hyperactive state 
induced an accumulation of the cells in the G2/M- phase of the 
cell cycle, polyploidization and subsequent apoptosis.28 29 At 
the pharmacological level, the selective SAE inhibitor ML-792 
phenocopies the genetic inhibition of the SUMOylation pathway 
and acts preferentially in MYC hyperactive states.35 Consistent 
with the above- mentioned data, we detected that ML-93, which 
shows a higher efficacy in cell- based PDAC models, acts in the 
nanomolar range, induced accumulation of cells in the G2/M 
phase, polyploidy and apoptosis. Furthermore, we provide 
multiple evidences for a preferential efficacy of ML-93 in MYC- 
hyperactivated PDACs. It has been described that MYC primes 
for sensitivity towards antimitotic drugs acting in the G2/M 
phase of the cell cycle,45 especially in the context of mutant 
KRAS,46 a ubiquitous genetic lesion in PDAC. In addition, genes 
relevant for mitotic control are enriched among MYC synthetic 
lethal genes,28 44 furthermore supporting the observation that 
MYC hyperactivation induces a vulnerability in this particular 
cell cycle phase. Congruently, the SUMO pathway is necessary 
for cell division and regulates mitotic chromosome structure, 
kinetochores, mitotic progression, chromosome separation and 
cytokinesis,47 explaining the synthetic lethal interaction of the 
SUMO pathway with MYC.
Although we detected a coexpression of MYC and SUMO in 
a PDAC subtype, it is important to note that especially in the 
IHC analysis there was evidence for an active SUMO pathway, 
measured as nuclear expression of SUMO1, that was also detected 
in PDAC with low MYC expression. The molecular drivers in 
this setting remain elusive so far. Vice versa, MYC positive PDAC 
with no activation of the SUMO pathway do also exist. In breast 
cancers, the SUMO pathway enzymes SAE1 and SAE2 mark a 
patient population with particular worse prognosis only in the 
MYC high subtype,28 an effect we did not observe in PDAC using 
SUMO proteins as discriminators. Such observations point to the 
complexity and context specific regulation of the MYC network. 
Here, MYC cofactors can add to the complexity and the under-
standing of the network. For example, the ATP- dependent 
nucleosome- remodelling factor component bromodomain PHD 
transcription factor BPTF was demonstrated to be necessary 
for the control of an MYC subnetwork in pancreatic cancer.48 
Such considerations might also implicate that the association of 
hyperactive MYC to one particular transcriptome- defined PDAC 
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Figure 5 SUMOylation inhibition in human PDAC ex vivo and in vivo models. (A–E) The human PDAC cell line PaTu- 8988T was used to generate 
murine xenograft models in NOG mice. (A) Mice were treated with 50 mg/kg ML-93 intravenously on d1,2 and d8,9 and (B) tumour size was 
measured over time. (C) Tumour size at D31 of ML-93- treated PaTu- 8988T- derived xenograft mice revealed significant reduction in tumour size in 
treated mice (n=5 mice in each group). Statistical significance was assessed using an unpaired Student’s t- test. *P<0.05. PaTu- 8988T tumours were 
treated with 50 mg/kg ML-93 intravenously on D1, 2 (D). Two days after the first injection (d3), tumours were harvested and proteins were analysed 
for sumoylated and un- SUMOylated RanGAP1 by Western blot (E). Tumour lysates of two vehicle- treated and two ML-93- treated animals were 
analysed tubulin: loading control. (F) Primary- dispersed human PDAC cells, HuPDAC3, HuPDAC7, HuPDAC17, were analysed for MYC expression by 
Western blotting; tubulin: loading control. (G) SUMO1 and SUMO2/3 Western blots of the indicated cell lines; tubulin: loading control. (H) Primary- 
dispersed human PDAC cells, HuPDAC3 and HuPDAC7 were analysed for the mRNA expression of MYC, CAD, ODC1, HSPE1 (MYC pathway) and 
SUMO1, SUMO2, SUMO3, SAE1, SAE2, UBE2I (SUMO pathway). mRNA expression was normalised to GAPDH and the mRNA expression in HuPDAC7 
was arbitrarily set to 1. Shown is the mean±SD of three independent experiments performed as technical triplicates. (I) GI50 for ML-93 and ML-792 
was determined in HuPDAC3, HuPDAC7, HuPDAC17 cells using CellTiter- Glo assay. A 7- point dilution (ML-93: 0–1000 nM; ML-792: 0–5000 nM) 
was used and cells were treated for 72 hours. The assay was performed with at least three biological replicates conducted as technical triplicates. 
GI50 values >1000 nM for ML-93 and >5000 nM for ML-792 were extrapolated from the fitted curve. (J, K) Clonogenic assay of HuPDAC3, HuPDAC7, 
HuPDAC17 cells treated with the indicated doses of ML-93 or vehicle. (E) Representative experiment is depicted; (F) Quantification of the clonogenic 
assay. Shown is the mean±SD of at least three biological replicates performed as duplicates. (L) Human HuPDAC3 and HuPDAC7 cells were treated 
with ML-93 (500 nM) or were left as vehicle treated controls. After 72 hours, the fraction of apoptotic cells was determined by annexin V/PI flow 
cytometric analysis. All annexin V positive and PI negative cells were rated as apoptotic. Shown is the fold induction determined as the relative 
increase in the apoptotic fraction versus DMSO control after 72 hours of treatment with ML-93. Three independent experiments performed as 
technical triplicates are shown and each experiment is depicted as a circle. P value of an unpaired t- test *<0.05; **<0.01. GI50, growth inhibitory; i.v., 
intravenous; PDAC, pancreatic ductal adenocarcinoma; SUMO, small ubiquitin- like modifier.
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subtype is less strict than anticipated and the net MYC activity is 
modulated by coexpression of cofactors and synthetically lethal 
interactors, a note recently described across human cancers.49 
The demonstration that MYC is central to plasticity processes 
in PDAC models,50 might furthermore underscore the need for 
MYC in diverse cellular states and phenotypes.
Despite multiple evidence for the synthetic lethal interaction 
of MYC and SUMO pathways, only one out of three MYC ‘high’ 
models responded to SUMOi in vivo. This phenomenon might 
be explained at several levels. Clear evidence, including the 
recent VIKTORY umbrella trial in gastric cancer,51 demonstrates 
that biomarker- driven patient selection to targeted therapies is 
successful. However, despite the presence of the marker, only a 
fraction of patients responds to the targeted intervention. This 
implicates that the biology associated with a particular marker 
must be analysed and understood in greater and mechanistic 
detail. Furthermore, two or more markers might increase the 
precision to select therapies in solid cancers, a note under-
scored by large cell- based screening efforts.52 The observation 
that PSN1 cells react in vivo with a trend for reduced prolif-
eration and increased caspase activity shortly after the SUMOi 
application, but SUMOi does not reduce tumour burden, might 
suggest that alternative treatment schedules should be tested to 
increase the efficacy of the treatment. Slow growth and small 
size of the investigated in vivo models might also impact on the 
efficacy. Furthermore, due to the ML-93- induced skin irritation 
and ulceration at the injection site observed in immunodeficient 
mice, we were not able to investigate extended treatment regi-
mens. Other explanations include problems of bioavailability 
of drugs and resistance mechanisms that are initiated in vivo. 
Several promising anticancer drugs, such as proteasome inhibi-
tors, HDAC inhibitors, heat- shock protein inhibitors and mitotic 
inhibitors, are potent in vitro but exhibit limited efficacy in solid 
cancers models in vivo. Reduced oxygen tension, metabolic 
supply, translation rate (and hence proteotoxic stress) and rate 
of proliferation of cell lines growing in vivo can be attributed to 
explain the discrepancy.53–56 Lastly, dual or triple combinations 
of targeted therapies are successfully used in the clinic. For BRAF- 
mutated melanomas, dual targeting of the driver pathway with an 
RAF and an MEK- inhibitor is FDA approved.57 In a recent safety 
lead- in analysis of the BEACON phase III clinical trial for BRAF 
mutant colorectal cancer promising efficacy of a triple targeted 
therapy with raf proto- oncogene, serine/threonine kinase (RAF), 
mitogen- activated protein kinase kinase (MEK) and epidermal 
growth factor receptor (EGFR)- inhibitors was observed.58 Such 
data suggest to develop SUMOi- based combination therapies by 
an unbiased pharmacological screening experiment to exploit 
MYC synthetic dosage lethality by a multiple- targeting approach.
We provide clear rationale for the future development of 
SUMOylation inhibitor- based therapies for a PDAC subgroup 
with coactivation of the SUMO pathway and MYC. This partic-
ular PDAC population is characterised by an aggressive disease, 
poor prognosis and the current lack of clear treatment options. 
Therefore, our study represents an important step in estab-
lishing SUMOi- based therapy as a potential approach to target 
an extremely dismal PDAC subtype.
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